Biocon Ltd.

Financial

	Biocon	Concord Biotech	Advanced Enzyme
Operational Metrics
Pharmaceutical Sector
Domestic Sales Growth - YoY	7.7 %	n/a	n/a
R&D as a % of Total Sales	6.0 %	2.26 %	7.5 %
Financials
5 yr Average ROE	7.26 %	20.02 %	12.01 %
5yr average Equity Multiplier	2.52	1.26	1.16
5yr Average Asset Turnover Ratio	0.35	0.52	0.42
5yr Avg Net Profit Margin	8.25 %	30.81 %	24.34 %
Price to Book	1.92	10.83	2.48
P/E	50.13	52.8	25.02
5yr Avg Cash Conversion Cycle	-144.7 Days	37.41 Days	87.24 Days
Inventory Days	93.33 Days	80.96 Days	72.86 Days
Days Receivable	119.85 Days	111.87 Days	58.11 Days
Days Payable	264.09 Days	173.13 Days	50.65 Days
5yr Average Interest Coverage Ratio	12.09	137.55	54.91
5yr Avg ROCE	7.9 %	25.59 %	16.0 %
5yr Avg Operating Profit Margin	19.41 %	42.97 %	38.48 %
5 yr average Debt to Equity	0.67	0.04	0.02
5yr CAGR Net Profit	6.45 %	12.77 %	0.61 %
5yr Average Return on Assets	3.07 %	15.93 %	10.35 %
Shareholdings
Promoter Holding	60.64 %	44.08 %	43.08 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	0.0	-9.62 %
Change in Mutual Fund Holding (3 Yrs)	5.25 %	-0.42 %	-1.1 %

Business

	Biocon	Concord Biotech	Advanced Enzyme
Product Wise Break-Up	Product Wise Break-Up Biosimilars 59.01 Syngene (Research Services) 24.1 Generics 16.89 Novel 0 Branded Formulations 0 Biologics 0 Formulations 0 API - Fermentation based 0 Specialized Manufacturing 0 Bio-process 0 Animal nutrition 0 Human nutrition 0	Product Wise Break-Up Formulations 28.0 Branded Formulations 0 Biologics 0 API - Fermentation based 72.0 Human nutrition 0 Syngene (Research Services) 0 Animal nutrition 0 Generics 0 Biosimilars 0 Novel 0 Specialized Manufacturing 0 Bio-process 0	Product Wise Break-Up Formulations 0 Branded Formulations 0 Biologics 0 API - Fermentation based 0 Human nutrition 64.0 Syngene (Research Services) 0 Animal Health 12.0 Generics 0 Biosimilars 0 Novel 0 Specialized Manufacturing 8.0 Bio-process 16.0
Location Wise Break-Up	Location Wise Break-Up USA 43.75 Ireland 23.83 Rest of the World 21.52 India 10.9 Asia (Ex India) 0 Europe 0	Location Wise Break-Up Ireland 0 Rest of the World 47.0 Asia (Ex India) 0 USA 0 Europe 0 India 53.0	Location Wise Break-Up Ireland 0 Rest of the World 0 Asia Pacific 9.0 USA 36.0 Europe 5.0 India 47.0 Others 3.0
Operating Profit Break-Up	Operating Profit Break-Up Others 100	-	-
Asset Break-Up	Asset Break-Up Biosimilars 75.68 Generics 13.68 Research 10.63 Novel Biologics 0 India 0 USA 0 Europe 0 Others 0.01	Asset Break-Up Research 0 Generics 0 Biosimilars 0 India 99.74 USA 0 Europe 0 Novel Biologics 0 Others 0.26	Asset Break-Up Research 0 Generics 0 Biosimilars 0 India 47.43 USA 43.57 Europe 9.0 Novel Biologics 0

Biocon Ltd.

SIGN UP FOR FREE